US approves 1st drug developed to prevent chronic migraines
TRENTON, N.J. (AP) - U.S. regulators have approved the first drug designed to prevent chronic migraines.
Thursday's action by the Food and Drug Administration clears the monthly shot for sale. Aimovig is the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills are being tested.
Current prevention treatments include pills originally developed for epilepsy and other conditions and the wrinkle reducer Botox, but many patients abandon them because they don't help much or cause serious side effects.
Migraines can cause disabling symptoms: throbbing headaches, nausea and vomiting, and sensitivity to light and sound.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
LSU pitcher Matt Beck gets his moment at the plate
Brusly baseball needs extra innings to win regional series with Jennings.
Southern Athletic Director Roman Banks talks about coaching search
Drew Brees and Sean Payton enjoy the Zurich Classic
Legendary Parkview coach Kenny Guillot passes away at 76